PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gasparin, F. ; Tietje, M.R.* ; Katab, E.* ; Nurdinova, A. ; Yuan, T. ; Chmyrov, A. ; Uluc, N. ; Jüstel, D. ; Bassermann, F.* ; Ntziachristos, V. ; Pleitez, M.A.

Label-free protein-structure-sensitive live-cell microscopy for patient-specific assessment of myeloma therapy.

Nat. Bio. Eng., DOI: 10.1038/s41551-025-01443-3 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
The efficacy of drug therapy in multiple myeloma is conventionally assessed by whole-cell-population methods, serum analysis of light chains and monoclonal antibodies, immunofixation electrophoresis, or by flow cytometry of bone marrow aspirates and biopsies. These methods provide relevant information on the presence of specific immunoglobulins at high sensitivity and specificity but require a large number of cells, involve long and laborious sample preparation steps, and provide only tumour bulk information. Here we develop a single-cell imaging technique requiring a reduced number of primary cells for longitudinal evaluation of patient-specific treatment and assessment of treatment heterogeneity. By exploiting the mechanistic action of proteasome inhibition and in synergy with the label-free protein-structure specificity of mid-infrared optoacoustic microscopy, we present a technology that facilitates longitudinal evaluation of myeloma treatment and a patient's heterogeneous response. Detecting optical-generated ultrasound waves that intensify with optical absorption, this technology allows observation of proteins in living cells with high sensitivity. Specifically, we use intermolecular β-sheet formation as a biomarker for cell viability during therapy and apply it to assess drug-treatment performance in multiple myeloma patients.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Human Multiple-myeloma; Infrared-spectroscopy; Proteasome Inhibitors; Ir; Conformation; Bortezomib; Apoptosis
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 2157-846X
e-ISSN 2157-846X
Zeitschrift Nature biomedical engineering
Verlag Nature Publishing Group
Verlagsort London ; New York NY ; Tokyo
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Biological and Medical Imaging (IBMI)
Institute of Computational Biology (ICB)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-505500-001
G-505594-001
G-503800-001
Förderungen European Research Council (ERC) under the European Union
German Research Foundation)
Deutsche Forschungsgemeinschaft (DFG
Deutsche Forschungsgemeinschaft (German Research Foundation)
DOI 10.1038/s41551-025-01443-3
WOS ID 001528314900001
Scopus ID 105010638212
PubMed ID 40659832
Erfassungsdatum 2025-07-22
[➜Korrektur melden]